Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Seres Therapeutics (MCRB) over the last 9 years, with Q3 2025 value amounting to 6403.7%.

  • Seres Therapeutics' EBITDA Margin changed N/A to 6403.7% in Q3 2025 from the same period last year, while for Sep 2025 it was 25706.84%, marking a year-over-year increase of 140978500.0%. This contributed to the annual value of 90.02% for FY2023, which is 34188100.0% up from last year.
  • Per Seres Therapeutics' latest filing, its EBITDA Margin stood at 6403.7% for Q3 2025.
  • Seres Therapeutics' EBITDA Margin's 5-year high stood at 53.83% during Q3 2021, with a 5-year trough of 64450.0% in Q4 2023.
  • In the last 4 years, Seres Therapeutics' EBITDA Margin had a median value of 3803.01% in 2022 and averaged 9228.92%.
  • Data for Seres Therapeutics' EBITDA Margin shows a peak YoY increase of 53637800bps (in 2023) and a maximum YoY decrease of -574048700bps (in 2023) over the last 5 years.
  • Quarter analysis of 4 years shows Seres Therapeutics' EBITDA Margin stood at 693.42% in 2021, then crashed by -916bps to 7045.13% in 2022, then tumbled by -815bps to 64450.0% in 2023, then surged by 90bps to 6403.7% in 2025.
  • Its EBITDA Margin was 6403.7% in Q3 2025, compared to 64450.0% in Q4 2023 and 15436.45% in Q3 2023.